Cinnabarinic and xanthurenic acids are kynurenine metabolites generated by oxidative dimerization of 3-hydroxyanthranilic acid and transamination of 3-hydroxykynurenine, respectively. Recent evidence suggests that both compounds can affect brain function and neurotransmission and interact with metabotropic glutamate (mGlu) receptors. Cinnabarinic acid behaves as an orthosteric agonist of mGlu4 receptors, whereas some of the in vitro and in vivo effects produced by xanthurenic acid appear to be mediated by the activation of mGlu2 and mGlu3 receptors. Cinnabarinic acid could play an important role in mechanisms of neuroinflammation acting as a linking bridge between the immune system and the CNS. Xanthurenic acid has potential implications in the pathophysiology of schizophrenia and is a promising candidate as a peripheral biomarker of the disorder. The action of cinnabarinic acid and xanthurenic acid may extend beyond the regulation of mGlu receptors and may involve several diverse molecular targets, such as the aryl hydrocarbon receptor for cinnabarinic acid and vesicular glutamate transporters for xanthurenic acid. The growing interest on these two metabolites of the kynurenine pathway may unravel new aspects in the complex interaction between tryptophan metabolism and brain function, and lead to the discovery of new potential targets for the treatment of neurological and psychiatric disorders.This article is part of the Special Issue entitled 'The Kynurenine Pathway in Health and Disease'. (C) 2016 Elsevier Ltd. All rights reserved.

Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors / Fazio, Francesco; Lionetto, Luana; Curto, Martina; Iacovelli, Luisa; Copeland, Caroline S.; Neale, Stuart A.; Bruno, Valeria Maria Gloria; Battaglia, Giuseppe; Salt, Thomas E.; Nicoletti, Ferdinando. - In: NEUROPHARMACOLOGY. - ISSN 1873-7064. - 112:Pt B(2016), pp. 365-372. [10.1016/j.neuropharm.2016.06.020]

Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors

Curto, Martina;Iacovelli, Luisa;Bruno, Valeria Maria Gloria;Battaglia, Giuseppe;Nicoletti, Ferdinando
2016

Abstract

Cinnabarinic and xanthurenic acids are kynurenine metabolites generated by oxidative dimerization of 3-hydroxyanthranilic acid and transamination of 3-hydroxykynurenine, respectively. Recent evidence suggests that both compounds can affect brain function and neurotransmission and interact with metabotropic glutamate (mGlu) receptors. Cinnabarinic acid behaves as an orthosteric agonist of mGlu4 receptors, whereas some of the in vitro and in vivo effects produced by xanthurenic acid appear to be mediated by the activation of mGlu2 and mGlu3 receptors. Cinnabarinic acid could play an important role in mechanisms of neuroinflammation acting as a linking bridge between the immune system and the CNS. Xanthurenic acid has potential implications in the pathophysiology of schizophrenia and is a promising candidate as a peripheral biomarker of the disorder. The action of cinnabarinic acid and xanthurenic acid may extend beyond the regulation of mGlu receptors and may involve several diverse molecular targets, such as the aryl hydrocarbon receptor for cinnabarinic acid and vesicular glutamate transporters for xanthurenic acid. The growing interest on these two metabolites of the kynurenine pathway may unravel new aspects in the complex interaction between tryptophan metabolism and brain function, and lead to the discovery of new potential targets for the treatment of neurological and psychiatric disorders.This article is part of the Special Issue entitled 'The Kynurenine Pathway in Health and Disease'. (C) 2016 Elsevier Ltd. All rights reserved.
2016
Cinnabarinic acid; Metabotropic glutamate receptors; Neuroinflammation; Schizophrenia; Xanthurenic acid
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Cinnabarinic acid and xanthurenic acid: Two kynurenine metabolites that interact with metabotropic glutamate receptors / Fazio, Francesco; Lionetto, Luana; Curto, Martina; Iacovelli, Luisa; Copeland, Caroline S.; Neale, Stuart A.; Bruno, Valeria Maria Gloria; Battaglia, Giuseppe; Salt, Thomas E.; Nicoletti, Ferdinando. - In: NEUROPHARMACOLOGY. - ISSN 1873-7064. - 112:Pt B(2016), pp. 365-372. [10.1016/j.neuropharm.2016.06.020]
File allegati a questo prodotto
File Dimensione Formato  
1-s2.0-S0028390816302738-main.pdf

accesso aperto

Note: Fazio_Cinnabarinic acid and xanthurenic acid_2016
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 356.57 kB
Formato Adobe PDF
356.57 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1688299
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 72
  • ???jsp.display-item.citation.isi??? 68
social impact